These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1563 related items for PubMed ID: 18609187
21. Inflammatory bowel disease in Iran: a review of 457 cases. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. J Gastroenterol Hepatol; 2005 Nov; 20(11):1691-5. PubMed ID: 16246187 [Abstract] [Full Text] [Related]
22. Clinicopathological study of colorectal cancer occurring in patients with ulcerative colitis: results from a single hospital in Japan. Fujita T, Ando T, Watanabe O, Hasegawa M, Miyake N, Kondo S, Kato T, Ishiguro K, Nakamura M, Miyahara R, Ohmiya N, Niwa Y, Goto H. Hepatogastroenterology; 2010 Nov; 57(99-100):487-92. PubMed ID: 20698214 [Abstract] [Full Text] [Related]
23. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B, IBSEN Study Group. Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104 [Abstract] [Full Text] [Related]
24. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Braden B, Halliday J, Aryasingha S, Sharifi Y, Checchin D, Warren BF, Kitiyakara T, Travis SP, Chapman RW. Clin Gastroenterol Hepatol; 2012 Mar; 10(3):303-8. PubMed ID: 22037429 [Abstract] [Full Text] [Related]
26. Dysplasia and cancer in inflammatory bowel disease. Basseri RJ, Basseri B, Papadakis KA. Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):59-66. PubMed ID: 21309672 [Abstract] [Full Text] [Related]
27. High lifetime risk of cancer in primary sclerosing cholangitis. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. J Hepatol; 2009 Jan; 50(1):158-64. PubMed ID: 19012991 [Abstract] [Full Text] [Related]
28. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein CN. Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762 [Abstract] [Full Text] [Related]
30. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Fausa O, Schrumpf E, Elgjo K. Semin Liver Dis; 1991 Feb; 11(1):31-9. PubMed ID: 2047887 [Abstract] [Full Text] [Related]
31. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gupta G, Gelfand JM, Lewis JD. Gastroenterology; 2005 Sep; 129(3):819-26. PubMed ID: 16143121 [Abstract] [Full Text] [Related]
32. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF. Aliment Pharmacol Ther; 2011 Sep; 34(5):497-508. PubMed ID: 21692821 [Abstract] [Full Text] [Related]
33. [Inflammatory bowel disease and colorectal cancer]. Hagymási K, Tulassay Z. Orv Hetil; 2006 Oct 15; 147(41):1977-82. PubMed ID: 17120688 [Abstract] [Full Text] [Related]
34. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Nørregaard P, Moesgaard F, Bendtsen F, Munkholm P, DCCD study group. Am J Gastroenterol; 2006 Jun 15; 101(6):1274-82. PubMed ID: 16771949 [Abstract] [Full Text] [Related]
35. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Sjöqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Löfberg R. Anticancer Res; 2004 Jun 15; 24(5B):3121-7. PubMed ID: 15510599 [Abstract] [Full Text] [Related]
36. Chemoprevention for colon cancer: new opportunities, fact or fiction? Terhaar Sive Droste JS, Tuynman JB, Van Dullemen HM, Mulder CJ. Scand J Gastroenterol Suppl; 2006 Jun 15; (243):158-64. PubMed ID: 16782636 [Abstract] [Full Text] [Related]
37. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. D'Haens GR, Lashner BA, Hanauer SB. Am J Gastroenterol; 1993 Aug 15; 88(8):1174-8. PubMed ID: 8338083 [Abstract] [Full Text] [Related]
38. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Bernstein CN, Blanchard JF, Metge C, Yogendran M. Am J Gastroenterol; 2003 Dec 15; 98(12):2784-8. PubMed ID: 14687833 [Abstract] [Full Text] [Related]
39. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Karlsen TH, Hampe J, Wiencke K, Schrumpf E, Thorsby E, Lie BA, Broomé U, Schreiber S, Boberg KM. Am J Gastroenterol; 2007 Jan 15; 102(1):115-21. PubMed ID: 17100974 [Abstract] [Full Text] [Related]
40. Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis. Averboukh F, Ziv Y, Kariv Y, Zmora O, Dotan I, Klausner JM, Rabau M, Tulchinsky H. Colorectal Dis; 2011 Nov 15; 13(11):1230-5. PubMed ID: 21689324 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]